Investment analysts at HC Wainwright boosted their FY2027 EPS estimates for shares of Oncolytics Biotech in a research report ...

Equities research analysts at Leede Financial boosted their FY2025 earnings per share (EPS) estimates for shares of ...

Oncolytics Biotech faces financial struggles and unclear pelareorep efficacy signals. Learn why ONCY stock's risks outweigh ...

CNW/ -- (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today ...

Q4 2024 Earnings Call Transcript March 7, 2025 Oncolytics Biotech Inc. beats earnings expectations. Reported EPS is $-0.06949, expectations were $-0.08. Operator: Good morning, and welcome to ...

Oncolytics Biotech Inc (ONCY) reports significant advancements in cancer research despite increased net loss and leadership uncertainties.

Oncolytics is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. Pelareorep has demonstrated promising results in two randomized ...

Oncolytics Biotech Inc. (ONCY) has been beaten down lately with too much selling pressure. While the stock has lost 9.3% over the past four weeks, there is light at the end of the tunnel as it is now ...